Radiobiology

El Camino Health is First in California to Offer Cancer Patients Innovative Ethos™ Adaptive Intelligence™ Radiation Technology

Retrieved on: 
Tuesday, June 8, 2021
Medicine, Clinical medicine, Neurosurgery, Medical specialties, Radiobiology, Medical physics, Radiosurgery, Cyberknife, Radiation therapy, Draft:Surface Guided Radiation Therapy, Stereotactic surgery

"The speed, precision and accuracy of this new technology is reshaping how we fight cancer," said Dr. Robert Sinha, director of the Center for Advanced Radiotherapy and Cyberknife Radiosurgery at El Camino Health.

Key Points: 
  • "The speed, precision and accuracy of this new technology is reshaping how we fight cancer," said Dr. Robert Sinha, director of the Center for Advanced Radiotherapy and Cyberknife Radiosurgery at El Camino Health.
  • "We've never had the ability with radiation treatment to look inside the body and see what's changing in real time, until now.
  • Ethos is the only technology that can customize radiation treatment plans in real time based on individual patient needs and anatomical changes.
  • El Camino Health's cancer radiation therapy program offers leading-edge radiation treatment options that are typically found exclusively in large academic institutions.

Elekta's new strategy to focus on growth and access to radiation therapy

Retrieved on: 
Monday, June 7, 2021
Health sciences, Medicine, Applied sciences, Medical physics, Radiation therapy, Radioactivity, Radiobiology, Treatment of cancer, Therapy, Cancer

Gustaf Salford said that he wanted to see more than 300 million people with cancer gaining access to radiation therapy, an integral part of most cancer treatments.

Key Points: 
  • Gustaf Salford said that he wanted to see more than 300 million people with cancer gaining access to radiation therapy, an integral part of most cancer treatments.
  • Although these countries comprise 85 percent of the global population, they only have 40 percent of the total installed base of radiation therapy devices.
  • Elekta's new strategy will also address improving radiation therapy technology and advanced techniques such as hypofractionation and adaptive treatments.
  • The Access 2025 strategy is built on four pillars: innovation, partner integration, customer focus and driving adoption of radiation therapy across the globe, reflecting Elekta's vision to create a world where everyone has access to the best cancer care.

Elekta's new strategy to focus on growth and access to radiation therapy

Retrieved on: 
Monday, June 7, 2021
Health sciences, Medicine, Applied sciences, Medical physics, Radiation therapy, Radioactivity, Radiobiology, Treatment of cancer, Therapy, Cancer

Gustaf Salford said that he wanted to see more than 300 million people with cancer gaining access to radiation therapy, an integral part of most cancer treatments.

Key Points: 
  • Gustaf Salford said that he wanted to see more than 300 million people with cancer gaining access to radiation therapy, an integral part of most cancer treatments.
  • Although these countries comprise 85 percent of the global population, they only have 40 percent of the total installed base of radiation therapy devices.
  • Elekta's new strategy will also address improving radiation therapy technology and advanced techniques such as hypofractionation and adaptive treatments.
  • The Access 2025 strategy is built on four pillars: innovation, partner integration, customer focus and driving adoption of radiation therapy across the globe, reflecting Elekta's vision to create a world where everyone has access to the best cancer care.

Telix to Present at the 2021 Jefferies Virtual Healthcare Conference

Retrieved on: 
Tuesday, June 1, 2021
Radiation therapy, Radioactivity, Radiobiology, Telix, Physical sciences, Natural sciences, Physics

Telix is a clinical-stage biopharmaceutical company focused on the development of diagnostic and therapeutic products using Molecularly Targeted Radiation (MTR).

Key Points: 
  • Telix is a clinical-stage biopharmaceutical company focused on the development of diagnostic and therapeutic products using Molecularly Targeted Radiation (MTR).
  • Telix is headquartered in Melbourne, Australia with international operations in Belgium, Japan, and the United States.
  • Telix is developing a portfolio of clinical-stage products that address significant unmet medical needs in oncology and rare diseases.
  • For more information visit www.telixpharma.com and follow Telix on Twitter (@TelixPharma) and LinkedIn .

NhTherAguix: NH TherAguix and the CHU Grenoble-Alpes announce the publication of the results of the First-In-Human phase 1 clinical trial on the combination of AGuIX with radiotherapy

Retrieved on: 
Monday, May 31, 2021
Medicine, Clinical medicine, Medical physics, Radiobiology, Brain tumor, Radiation therapy, Radioactivity, Brain metastasis, Prophylactic cranial irradiation, Limited-stage small cell lung carcinoma

NH TherAguix and the CHU Grenoble-Alpes announce the publication of the results of the First-In-Human phase 1 clinical trial on the combination of AGuIX with radiotherapy on multiple brain metastases patients.

Key Points: 
  • NH TherAguix and the CHU Grenoble-Alpes announce the publication of the results of the First-In-Human phase 1 clinical trial on the combination of AGuIX with radiotherapy on multiple brain metastases patients.
  • All patients have received one intravenous injection of AGuIX associated with a conventional whole brain radiation therapy (10 x 3 Gy).
  • This trial has demonstrated that the combination of AGuIX with radiotherapy for these patients is safe and feasible.
  • Thus, the dose of 100 mg/kg, reached without occurrence of dose limiting toxicities, was selected for the phase II trial that is currently ongoing.

Researchers prepare to send fungi for a ride around the moon

Retrieved on: 
Friday, May 28, 2021
Branches of biology, Biology, Life sciences, Senescence, Cellular processes, Molecular genetics, Mutation, Radiobiology, Melanin, DNA repair, DNA, Radiation therapy

Naval Research Laboratory are preparing experimental samples of fungi to send for a ride around the moon tentatively scheduled for later in 2021 or early 2022.

Key Points: 
  • Naval Research Laboratory are preparing experimental samples of fungi to send for a ride around the moon tentatively scheduled for later in 2021 or early 2022.
  • Fungi have natural mechanisms to protect from and repair DNA damage caused by radiation.
  • Those mechanisms enable the fungi to withstand several hundred times more radiation than humans.
  • This experiment will study the melanin in fungi (which may assist in protecting them from damage), as well as DNA repair pathways (which repair damage once it occurs).

RayCare 5A brings new features for radiation therapy management

Retrieved on: 
Thursday, May 27, 2021
Health sciences, Medical physics, Applied sciences, Natural sciences, Radiobiology, Radiation therapy, Radioactivity, Workflow, Therapy

RayCare 5A* introduces a range of significant new features, including several advancements focused on managing the radiation therapy flow at clinics.

Key Points: 
  • RayCare 5A* introduces a range of significant new features, including several advancements focused on managing the radiation therapy flow at clinics.
  • Further additions to RayCare 5A include patient chart features such as radiation therapy treatment history, improved patient progress tracking, and support for documenting comorbidities.
  • Johan Lf, RaySearch founder and CEO states, "RayCare 5A takes an important step forward with significant features that improve the radiation therapy workflow.
  • The system efficiently coordinates activities in radiation therapy and offers advanced features for clinical workflow automation, and adaptive radiation therapy.

RayStation latest release, ­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­now with support for Accuray's CyberKnife® System

Retrieved on: 
Wednesday, May 26, 2021
Medicine, Clinical medicine, Medical specialties, Neurosurgery, Medical physics, Radiobiology, Radiation therapy, Radiosurgery, Cyberknife, Stereotactic surgery, Radiation treatment planning, Collimator

STOCKHOLM, May 26, 2021 /PRNewswire/ -- RaySearch announces the release of RayStation* 11A, the latest version of RaySearch's advanced treatment planning system.

Key Points: 
  • STOCKHOLM, May 26, 2021 /PRNewswire/ -- RaySearch announces the release of RayStation* 11A, the latest version of RaySearch's advanced treatment planning system.
  • Significant new functionality includes treatment planning for Accuray's CyberKnife System for radiosurgery and stereotactic body radiation therapy (SBRT).
  • RayStation provides support for optimization with the three different collimation types fixed cone, Iris and Incise Multileaf collimator and all CyberKnife tracking techniques for Synchrony real-time motion synchronization.
  • RaySearch markets the RayStation treatment planning system (TPS) and the oncology information system (OIS) RayCare.

Galera to Present at the Jefferies Virtual Healthcare Conference

Retrieved on: 
Wednesday, May 26, 2021
Life sciences, Health sciences, Natural sciences, Medical physics, Radiation therapy, Radioactivity, Radiobiology, Therapy, Biopharmaceutical

A live webcast of the presentation will be accessible from the Investors page of Galeras website, investors.galeratx.com .

Key Points: 
  • A live webcast of the presentation will be accessible from the Investors page of Galeras website, investors.galeratx.com .
  • Galera Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutic candidates that have the potential to transform radiotherapy in cancer.
  • The FDA granted Fast Track and Breakthrough Therapy designations to avasopasem for the reduction of SOM induced by radiotherapy.
  • Galera is headquartered in Malvern, PA. For more information, please visit www.galeratx.com .

Single Dose Radiotherapy Services Market Forecast, Trend Analysis & Opportunity Assessment 2020-2030 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, May 19, 2021
Radiology, Pharmaceutical, Health, Oncology, Physical sciences, Medical physics, Natural sciences, Chemistry, Radiobiology, Radiation therapy, Radioactivity, Cobalt

Global Single Dose Radiotherapy Services Market Analysis 2015-2019 and Forecast 2020-2030, By Indication\n8.

Key Points: 
  • Global Single Dose Radiotherapy Services Market Analysis 2015-2019 and Forecast 2020-2030, By Indication\n8.
  • Global Single Dose Radiotherapy Services Market Analysis 2015-2019 and Forecast 2020-2030, By Therapy\n9.
  • Global Single Dose Radiotherapy Services Market Analysis 2015-2019 and Forecast 2020-2030, By Service Provider\n10.
  • Global Single Dose Radiotherapy Services Market Analysis 2015-2019 and Forecast 2020-2030, by Region\nResearchAndMarkets.com is the world's leading source for international market research reports and market data.